New shot shows promise for severe eczema sufferers
NCT ID NCT07321951
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests an experimental drug called SHR-1819 in 201 adults with moderate-to-severe atopic dermatitis (eczema). The goal is to see if it can significantly improve skin symptoms and reduce itching. Participants receive either the drug or a placebo, and researchers track skin clearance and side effects over time.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MODERATE-TO-SEVERE ATOPIC DERMATITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Dermatology Hospital of Southern Medical University
Guangzhou, Guangdong, 510091, China
-
Hangzhou Third People's Hospital
Hangzhou, Zhejiang, 310009, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new pill tame tough eczema? a large trial aims to find out
- New shot could tame tough eczema by calming overactive immune cells
- New drug aims to calm severe eczema without steroids
- New drug shows promise for severe eczema in toddlers
- Eczema drug nemolizumab put to the vaccine test
- New shot could tame severe eczema in kids